Skip to main content
AMGN
NASDAQ Life Sciences

Amgen Tops Q2 Forecasts, Lifts Outlook; Pipeline Gains Offset by TAVNEOS Uncertainty

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$392.108
Mkt Cap
$210.497B
52W Low
$269.77
52W High
$398
52W Position info
45% above low
Off High info
1.5% below high
Rel. Volume info
1.3× avg
Market data snapshot near publication time

AMGN sits 45% above its 52-week low of $269.77.

Summary

Amgen reported Q2 2026 revenue of $10.1B and non-GAAP EPS of $6.29, beating estimates, and raised full-year guidance. The pipeline update featured progress in obesity and oncology, but TAVNEOS regulatory risk remains.

Updates

  1. · SEC 10-Q — 10-Q discloses TAVNEOS developed-product-technology rights carrying value of $2.4 billion as of June 30, 2026, with $2.3 billion related to the U.S. market.


Key Events · Earnings and Guidance · AMGN

  • Q2 Earnings Beat

    Total revenues of $10.1B (+10% YoY) and non-GAAP EPS of $6.29 beat consensus estimates of $5.62. GAAP EPS was $4.37, up 65% YoY.

  • Raised Full-Year Guidance

    2026 revenue guidance raised to $38.2B-$39.4B; non-GAAP EPS guidance raised to $22.30-$23.50, reflecting confidence in growth drivers.

  • Free Cash Flow Surge

    Free cash flow reached $3.5B in Q2, up from $1.9B a year ago, driven by business performance and lapping of a repatriation tax payment.

  • Pipeline Progress and Setbacks

    MariTide obesity program advancing with multiple Phase 3 trials; AMG 513 discontinued; subcutaneous blinatumomab studies on partial clinical hold.


Analysis · AMGN · Life Sciences

A strong second quarter saw Amgen surpass consensus with revenue of $10.1B and non-GAAP EPS of $6.29. The company raised its full-year revenue and EPS guidance, underscoring confidence in its growth trajectory. Free cash flow surged to $3.5B, providing ample capital for pipeline investment. However, the ongoing TAVNEOS regulatory saga and a recent cybersecurity breach add risk. The pipeline update highlights MariTide's broad Phase 3 program in obesity, but the discontinuation of AMG 513 and a partial clinical hold on subcutaneous blinatumomab are setbacks. Overall, the earnings beat and raised guidance are positive, but the stock is near its 52-week high, and the TAVNEOS overhang persists.

How filings like this one have moved

In the 30 days to Nov 9, 2026, 47.1% of the 1533 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AMGN was trading at $392.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $210.5B. The 52-week trading range was $269.77 to $398.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AMGN - Latest Insights

AMGN
Nov 05, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $477.40
Real-time Price: $465.00 info
Change: -$12.40 (-3%) info
Market Cap: $251.648B info
AMGN
Nov 03, 2026, 6:37 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $464.92
Real-time Price: $465.00 info
Change: +$0.080 (+0.02%) info
Market Cap: $251.648B info
AMGN
Nov 03, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $463.00
Real-time Price: $465.00 info
Change: +$2.00 (+0.43%) info
Market Cap: $251.648B info
AMGN
Nov 03, 2026, 4:01 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $460.57
Real-time Price: $465.00 info
Change: +$4.43 (+0.96%) info
Market Cap: $251.648B info
AMGN
Oct 26, 2026, 9:23 AM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $448.79
Real-time Price: $465.00 info
Change: +$16.21 (+4%) info
Market Cap: $251.648B info